Use of TaqMan Array Card for the Detection of Respiratory Viral Pathogens in Children under 5 Years Old Hospitalised with Acute Medical Illness in Ballabgarh, Haryana, India

Bharti Gaur**, Siddhartha Saha¹, A. Danielle Iuliano², Sanjay K. Rai³, Anand Krishnan³, Seema Jain¹, Brett Whitaker⁴, Jonas Winchell⁵, Renu B. Lal¹, Shobha Broor**

**Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India

¹Influenza Division, Centers for Disease Control and Prevention, U.S Embassy, New Delhi, India

²Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

³Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India

⁴Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

⁵Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Abstract

Historical specimens collected from hospitalized children were tested for the following 13 viruses: influenza A and B; respiratory syncytial virus (RSV); parainfluenza viruses 1–3; human metapneumovirus; rhinovirus; coronaviruses 229E, OC43, NL63 and HKU1 and Adenovirus using monoplex real-time reverse transcriptase polymerase chain reaction (rRT-PCR). They were retested using TaqMan Array Card (TAC), a micro-fluidic system, capable of simultaneous multi-pathogen testing, to evaluate its sensitivity and specificity against monoplex rRT-PCR. TAC showed high sensitivity (71%–100%) and specificity (98%–100%) for these viruses in comparison to monoplex rRT-PCR. Multi-specimen detection with high sensitivity and specificity makes TAC a potentially useful tool for both surveillance and outbreak investigations.

Keywords

Micro-fluidic card; sensitivity; specificity; viral pathogen diagnosis

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 4.0 License, which allows others remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Address for correspondence: Dr. Bharti Gaur, Centre for Community Medicine, All India Institute Of Medical Sciences, New Delhi - 110 029, India. ggaur.bharti@gmail.com.

Conflicts of interest

There are no conflicts of interest.
INTRODUCTION

The TaqMan array card (TAC) (Thermo Fisher, Carlsbad CA), a real-time reverse transcriptase polymerase chain reaction (rRT-PCR) platform in a 384-well micro-fluidic card format, is one of the available platforms, which allows rapid and simultaneous detection of multiple pathogens. TAC utilises rRT-PCR assays that are pre-spotted and dried in each individual well according to the end user’s design layout.\(^1\),\(^2\)

TAC has been studied for its application for infectious diseases, especially outbreak investigations by the U.S. Centers for Disease Control and Prevention (CDC).\(^3\),\(^4\) However, studies in different settings, including low- and middle-income countries, are limited.\(^5\) We compared the sensitivity and specificity of TAC with monoplex rRT-PCR performed in a 96-well PCR plate format as reference for the detection of 13 common respiratory viruses.

MATERIALS AND METHODS

Study design and specimens selection for TaqMan Array card testing

Nasal and throat specimens (only nasal swabs from infants) were collected from the hospitalised children with any acute medical illness within 24 hours of admission using polyester swabs (Thermo Fisher Inc., China),\(^6\) to test for respiratory pathogens using rRT-PCR; study details were published previously.\(^7\) Of the 298 previously tested samples, 135 specimens were selected, which were either positive for at least one pathogen by rRT-PCR or negative for all viruses tested, had been subjected to no more than two freeze-thaw cycles, had cycle threshold (Ct) values (18–38) and had sufficient sample volume (>200 μl).

Molecular testing of viruses using real-time reverse transcriptase polymerase chain reaction and TaqMan Array card

The steps involved in both the methods are compared in Table 1. The TAC used in this study was designed to test six specimens and included negative temperature coefficient, positive temperature coefficient, internal plate control and a panel of 31 monoplex rRT-PCR assays for 16 viral and 14 bacterial targets. A total volume of 100 μl of master-mix and total nucleic acid (TNA) was loaded. Final volume of master-mix contained similar concentration of primer and probe as in rRT-PCR. Primers and probes used were designed and synthesised at CDC.\(^2\),\(^8\) Clinical and analytical validations for each assay (sensitivity, specificity and limit of detection) have also been determined at CDC.\(^2\)

The reaction mixes for each specimen were prepared in a clean assay setup room, using AgPath-ID One-step RT-PCR kits as per the CDC protocol.\(^2\) All TAC runs were performed on the Thermo Fisher Scientific Inc., ViiA™ 7 real-time PCR instrument using the AgPath-ID One-Step RT-PCR kit (Thermo Fisher Scientific Inc., Foster City, CA). A Ct value of 43 was considered as cut-off value for interpretation as positive or negative for both the methods.

Statistical analysis

Sensitivity and specificity of the TAC for different pathogens were analysed using Stata 12 (StataCorp LP version 12, College Station, Texas, US) with monoplex rRT-PCR results.
as reference. The concordance between TAC and rRT-PCR for each pathogen in the same specimen was assessed using Cohen’s kappa coefficient.[9]

**RESULTS**

As summarised in Table 1, using monoplex rRT-PCR, the total time was 9–10 h, whereas TAC required ~3–4 h to complete the testing. Of 135 specimens tested using monoplex rRT-PCR assays, 85 (63%) specimens were found positive including nine specimens with co-detections, whereas 81 (60%) specimens were found positive including eight co-detections using TAC. Using monoplex rRT-PCR, respiratory syncytial virus (RSV) (33, 24%) was most commonly detected, followed by rhinovirus (Rhiv) (16, 12%); influenza B (8, 6%) and influenza A, adenovirus (AdV), parainfluenza viruses (PIV), human metapneumovirus (hMPV) and coronaviruses (CoV) (7 each, 5%). Using TAC, RSV remained the most commonly detected virus (29, 22%), followed by Rhiv (16, 12%), influenza A and B viruses (8 each, 6%), AdV (7, 5%), PIV (7, 5%), hMPV (6, 4%) and CoV (6, 4%).

In comparison to rRT-PCR, sensitivity and specificity of TAC ranged between 72%–100% and 98%–100%, respectively [Figure 1]. The highest sensitivity of TAC was for influenza A and B viruses (100%) and lowest for PIV (71%) and AdV (71%). Positive predictive value was highest for influenza B, RSV, hMPV and CoV (each 100%) and lowest for AdV (71%) and PIV (71%) using the TAC assay. RSV (96%) had the lowest negative predictive value, but all negative predictive values were relatively high (98%–100%). Cohen’s kappa coefficient ranged from 0.69 to 1.0 for different pathogens and was lowest for AdV (0.69, 95% confidence interval [CI]: 0.4–0.9) and PIV (0.69, 95% CI: 0.4–0.9) and highest for influenza B virus (1.0, one-sided CI: 1.0).

**DISCUSSION**

In this study, we observed that TAC offers several advantages over monoplex rRT-PCR while maintaining high sensitivity (71%–100%) and specificity (98%–100%) for the respiratory pathogen assays assessed similar to earlier studies.[1,2] Advantages of the TAC included a simple setup, lower specimen volume requirement, efficient consumption of TNA extracts and rRT-PCR reaction reagents and rapid, simultaneous detection of multiple pathogens in a single experiment. The TAC format due to its closed system design requiring less handling of assay and primers/probes minimises the risk for user error and cross-contamination besides requiring fewer tubes.[4,10,11] Furthermore, the TAC can be customised with different assays and configurations, unlike other commercial multi-pathogen detection platforms, which is useful in research settings, conducting disease surveillance or investigating outbreaks of unknown aetiology.[4,8] Conventional monoplex rRT-PCR assays for the detection of respiratory viruses can be tedious, expensive and require large volumes of biological specimens.[2,12] In comparison with monoplex rRT-PCR assays, TAC required 1/3 times less volume of TNA for detecting the same number of pathogens.[8,12]

While the kappa statistic indicated substantial to perfect agreement for all viral pathogens, assays for AdV and PIV showed lower agreement between the two methods (kappa 0.69)
compared to assays for the other respiratory viruses. This could be due to several factors such as, but not limited to, assay optimisation on different annealing temperatures and evaporation of reaction volume from incomplete card sealing, which can cause fluorescent anomalies or probe instability. Furthermore, the freeze-thaw degradation of specimens for retesting via TAC may have led to false-negative results.

One of the limitations of our study was wide CIs around the point estimates for TAC sensitivity for CoV, hMPV and PIV, because of few positive samples. Some viruses were not very prevalent, including PIV and CoV, making it difficult to interpret their sensitivity and specificity. We could test for 135 specimens out of 298 because of limited number of cards available for this study.

In spite of higher throughput of TAC card than rRT-PCR when used for multiple pathogens, its use in low-resource settings may not yet be feasible because of the high cost of ViiA™ 7 machine. Further, in case of failure of an assay for even one target pathogen, the entire set of targets in the card have to be repeated, unlike in monoplex, where individual wet assay can be performed for failed targets, which also makes TAC expensive.

In spite of these limitations, our study demonstrated that TAC results were comparable to monoplex rRT-PCR testing, but took less time for simultaneous detection of common respiratory viruses which might be useful during outbreak investigations.

**Financial support and sponsorship**

This study was supported in part by cooperative agreements U01 IP000206 from the Centers for Disease Control and Prevention, Atlanta, US.

**REFERENCES**

1. Weinberg GA, Schnabel KC, Erdman DD, Prill MM, Iwane MK, Shelley LM, et al. Field evaluation of TaqMan Array Card (TAC) for the simultaneous detection of multiple respiratory viruses in children with acute respiratory infection. J Clin Virol 2013;57:254–60. [PubMed: 23608639]
2. Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, et al. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol 2011;49:2175–82. [PubMed: 21471348]
3. Centers for Disease Control and Prevention (CDC). Unexplained Respiratory Disease Outbreak Working Group activities – Worldwide, March 2007-September 2011. MMWR Morb Mortal Wkly Rep 2012;61:480–3. [PubMed: 22763885]
4. Liu J, Ochieng C, Wiersma S, Ströher U, Towner JS, Whitmer S, et al. Development of a TaqMan array card for acute-febrile-illness outbreak investigation and surveillance of emerging pathogens, including ebola virus. J Clin Microbiol 2016;54:49–58. [PubMed: 26491176]
5. Saha SK, Islam MS, Qureshi SM, Hossain B, Islam M, Zaidi AK, et al. Laboratory methods for determining etiology of neonatal infection at population-based sites in South Asia: The ANISA study. Pediatr Infect Dis J 2016;35:S16–22. [PubMed: 27070058]
6. Kim C, Ahmed JA, Eidex RB, Nyoka R, Waiboci LW, Erdman D, et al. Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by real-time reverse transcription-PCR assays. PLoS One 2011;6:e21610. [PubMed: 21738731]
7. Broor S, Dawood FS, Pandey BG, Saha S, Gupta V, Krishnan A, et al. Rates of respiratory virus-associated hospitalization in children aged<5 years in rural Northern India. J Infect 2014;68:281–9. [PubMed: 24269675]
8. Harvey JJ, Chester S, Burke SA, Ansbro M, Aden T, Gose R, et al. Comparative analytical evaluation of the respiratory TaqMan array card with real-time PCR and commercial multi-pathogen assays. J Virol Methods 2016;228:151–7. [PubMed: 26640122]

9. McHugh ML. Interrater reliability: The Kappa statistic. Biochem Med (Zagreb) 2012;22:276–82. [PubMed: 23092060]

10. Salez N, Vabret A, Leruez-Ville M, Andreoletti L, Carrat F, Renois F, et al. Evaluation of four commercial multiplex molecular tests for the diagnosis of acute respiratory infections. PLoS One 2015;10:e0130378. [PubMed: 26107509]

11. Diaz MH, Cross KE, Benitez AJ, Hicks LA, Kutty P, Bramley AM, et al. Identification of bacterial and viral codetections with mycoplasma pneumoniae using the TaqMan array card in patients hospitalized with community-acquired pneumonia. Open Forum Infect Dis 2016;3:ofw071. [PubMed: 27191004]

12. Loeffelholz MJ, Pong DL, Pyles RB, Xiong Y, Miller AL, Bufton KK, et al. Comparison of the filmArray respiratory panel and prodesse real-time PCR assays for detection of respiratory pathogens. J Clin Microbiol 2011;49:4083–8. [PubMed: 21998418]
Figure 1:
Sensitivity, specificity and Cohen’s Kappa coefficient for the detection of selected respiratory viruses using TaqMan Array card compared to real-time reverse transcriptase polymerase chain reaction.
*Note: For some viruses, monoplex real-time reverse transcriptase polymerase chain reaction and TaqMan Array card identified different specimens as positive, so the sensitivity and specificity are not 100%
Table 1:
Comparison of methods for TaqMan Array Card assays with monoplex real-time reverse transcriptase polymerase chain reaction assays for respiratory viral pathogens

| Molecular tools         | rRT PCR                                      | TAC                        |
|-------------------------|----------------------------------------------|----------------------------|
| Extraction platform     | Roche MagNA Pure LC 2.0 (Roche, Indianapolis, US) | Magna Pure Compact (Roche Diagnostics, Indianapolis, USA) |
| Extraction protocol     | 100 μL TNA was extracted from 100 μL of clinical specimen as per manufacturer’s instructions | 100 μL TNA was extracted from 100 μL of stored clinical specimen as per manufacturer’s instructions |
| Primer and probe used   | Primers and probes used, were designed and synthesised at CDC | Primers and probes used, were designed and synthesised at CDC6. Clinical and analytical validations for each assay (sensitivity, specificity and LOD) has also been determined at CDC5 |
| PCR cycling conditions  | The thermo-cycling conditions for influenza A and B assays were: 50°C for 30 min, 95°C for 10 min, and 45 cycles of 95°C for 15 s, and 55°C for 30 s with data collection. For other viral assays, the thermo-cycling conditions were: 45°C for 10 min, 94°C for 10 min, and 45 cycles of 94°C for 30 s followed by 60°C for 1 min with data collection | Cycling conditions on the ViiA™ 7 for TACs were 45°C for 10 min, 95°C for 10 min, followed by 45 two-step cycles of 95°C for 20 s and 60°C for 1 min with data collection |
| Interpretation of test  | A Ct cut-off value of 43 was established and Ct values were interpreted as follows: positive results included Ct values <43, negative results included Ct values ≥43, and samples with no amplification detected were considered negative | A Ct cut-off value of 43 was established and Ct values were interpreted as follows: positive results included Ct values <43, negative results included Ct values ≥43, and samples with no amplification detected were considered negative |
| Time taken to perform the complete run | 9-10 h | 3-4 h |

rRT PCR: Real-time reverse transcriptase polymerase chain reaction, TNA: Total nucleic acid, TAC: TaqMan Array card, LOD: Limit of detection, CDC: Centers for disease control and prevention, Ct: Cycle threshold